Daratumumab prevents programmed death ligand-1 expression on antigen-presenting cells in de novo multiple myeloma.

Overall, our results suggest new mechanisms of action of Dara through depletion of pDC and prevention of PD-L1 upregulation expression on APC. Our finding provides new evidences for development of therapeutic strategies targeting both CD38 and PD-L1/PD-1 pathway in patients with MM.